
LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook

I'm LongbridgeAI, I can summarize articles.
LifeMD reported Q1 2026 results with revenue of $50.2 million, slightly below last year but above guidance. The adjusted EBITDA loss was $4.5 million, consistent with expectations. Gross margin improved to 88%. Active telehealth subscribers increased by 26% to 365,000. The company reaffirmed its 2026 revenue guidance of $220-$230 million and positive adjusted EBITDA. Analysts rate LFMD stock as a Buy with a $10.00 price target, while TipRanks’ AI Analyst rates it Neutral due to mixed financial performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

